1. Home
  2. LPA vs ACRV Comparison

LPA vs ACRV Comparison

Compare LPA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$2.60

Market Cap

83.2M

Sector

N/A

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.48

Market Cap

74.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
ACRV
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
74.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
LPA
ACRV
Price
$2.60
$2.48
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$14.67
AVG Volume (30 Days)
29.3K
431.3K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$47,536,343.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.20
P/E Ratio
$12.44
N/A
Revenue Growth
7.28
N/A
52 Week Low
$2.55
$1.05
52 Week High
$11.16
$8.00

Technical Indicators

Market Signals
Indicator
LPA
ACRV
Relative Strength Index (RSI) 35.71 55.77
Support Level $2.65 $2.12
Resistance Level $2.94 $2.59
Average True Range (ATR) 0.17 0.19
MACD 0.00 -0.00
Stochastic Oscillator 2.38 59.17

Price Performance

Historical Comparison
LPA
ACRV

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: